Attention Investors
Kindly note the Change in PAY IN for BSE A/C No. : 1201250000000691 (CDSL), if you have an NSDL A/C, kindly use INTER DEPOSITORY SLIP. For assistance, please call OR contact: Mr. Dadu, 98339 89807 / 022-6145 1000.    |   Exchanges / Depository: Prevent Unauthorized Transactions in your Trading / Demat account --> Update your Mobile Numbers / email IDs with your Stock Brokers / Depository Participant. Receive alerts on your Registered Mobile / email IDs for trading account transactions and all debit and other important transactions in your demat account directly from Exchange / Depository on the same day ......................Issued in the interest of Investors."     |    KYC : "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."     |    ASBA-IPO : "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
 ««+1  ««-1
 
 
Astrazeneca Pharma India LtdIndustry : Pharmaceuticals - Multinational
BSE Code:506820NSE Symbol: ASTRAZENP/E(TTM):89.62
ISIN Demat:INE203A01020Div & Yield %:0.39EPS(TTM):92.47
Book Value(Rs):319.6Market Cap ( Cr.):20718.38Face Value(Rs):2
    Change Company 
Date Headline
05-Jan-26 Volumes jump at Timken India Ltd counter
18-Dec-25 AstraZeneca Pharma gets CDSCO nod for import and sale of Datverzo in India
18-Nov-25 AstraZeneca partners with Sun Pharma for second SZC brand in India
17-Nov-25 Astrazeneca Pharma and Sun Pharma form second brand partnership
10-Nov-25 AstraZeneca Pharma slides after Q2 PAT decline 2% QoQ
08-Nov-25 Astrazeneca Pharma India standalone net profit rises 41.09% in the September 2025 quarter
27-Oct-25 Astrazeneca Pharma India to discuss results
15-Oct-25 Astrazeneca Pharma India Ltd - Launch Of Sodium Zirconium Cyclosilicate Powder For Oral Suspension 5G (Lokelma)
06-Oct-25 AstraZeneca Pharma gets CDSCO nod for Enhertu
03-Oct-25 Astrazeneca Pharma India Ltd - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) ..
<< < 1 2 3 4   > >>